How and when does an anticancer drug leave its binding site?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28580424.
- Also identified by DOI 10.1126/sciadv.1700014 and PMC identifier 5451192.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Obtaining atomistic resolution of drug unbinding from a protein is a much sought-after experimental and computational challenge. We report the unbinding dynamics of the anticancer drug dasatinib from c-Src kinase in full atomistic resolution using enhanced sampling molecular dynamics simulations. We obtain multiple unbinding trajectories and determine a residence time in agreement with experiments. We observe coupled protein-water movement through multiple metastable intermediates. The water molecules form a hydrogen bond bridge, elongating a specific, evolutionarily preserved salt bridge and enabling conformation changes essential to ligand unbinding. This water insertion in the salt bridge acts as a molecular switch that controls unbinding. Our findings provide a mechanistic rationale for why it might be difficult to engineer drugs targeting certain specific c-Src kinase conformations to have longer residence times.
Medical subject headings
- Antineoplastic Agents
- Dasatinib
- Neoplasm Proteins
- Protein Kinase Inhibitors
- src-Family Kinases